Leukemia (Adult)
A Phase I Open-Label Single-Dose Study of Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R{beta} Subunit (CD122) in T-Cell Large Granular Lymphocytic Leukemia
NCI-04-C-0089
Print this page
Investigator(s): |
John C. Morris, M.D. Principal Investigator Phone: 301-402-2912 jmorris@mail.nih.gov
|
Thomas Waldmann, M.D. Protocol Chair Phone: 301-496-6656 tawald@helix.nih.gov
|
|
|
Suzanne Fioravanti, R.N., B.S.N., O.C.N. Research Nurse Phone: 301-594-6544 Fax: 301-402-1001 fioravas@mail.nih.gov
|
Guinevere Chun, R.N., B.S.N., O.C.N. Research Nurse Phone: 301-451-7868 Fax: 301-402-1001 gchun@mail.nih.gov
|
|
|
Primary Eligibility:
- Histologically or cytologically confirmed T-cell large granular lymphocytic (T-LGL) leukemia
- T-LGL-associated hemocytopenia
- No symptomatic CNS involvement by leukemia
- ≥ 4 weeks since prior interferon, chemotherapy, and/or cyclosporine
- No NY Heart Association class III or IV CHF
Treatment Plan:
- Patients will receive monoclonal antibody Mik-beta-1 intravenously over 90 minutes on Day 1 followed by monitoring for side effects, blood levels of the antibody, receptor saturation with the antibody, serum chemistries and blood counts for 6 weeks
- Cohorts of 3-6 patients will receive escalating doses of monoclonal antibody Mik-beta-1 until the maximum tolerated dose (MTD) is determined
- Patients will be followed weekly for 6 weeks and then every 3 months for 9 months
Additional Information:
- This trial will be conducted at the NIH Clinical Center in Bethesda, MD. It is open to patients who meet the eligibility requirements, regardless of where they live in the United States.
- There is no charge for medical care received at NIH Clinical Center.
- FAQs about this study - provides information for patients about the trial such as frequency and duration of visits, costs, how to enroll, treatment plan.
- PDQ (Physicians Data Query) - provides additional details about this study for health care providers.
Reviewed: 6/18/08
Updated: 12/11/06